Portal
Order

MI Cancer Seek® is now available for clinical ordering. Learn more.

Home / Research / Publications / A pan-cancer analysis of impact of MDM2/MDM4 on immune checkpoint blockade (ICB)

Publications

Back

A pan-cancer analysis of impact of MDM2/MDM4 on immune checkpoint blockade (ICB)

– Caris Life Sciences

Poster

Key Finding:

MDM2 and MDM4 amplification are negative prognostic factors in TP53-wildtype breast cancer, while MDM4 amplification is associated with reduced survival in immune checkpoint blockade-treated non-small cell lung cancer. 

Download Publication

Discover
More

  • Characterization of MET Exon 14 Skipping Analog (Y1003) in Non-Small Cell Lung Cancer (NSCLC)

    – Caris Life Sciences

    Poster

    Abstract Introduction: Genomic alterations in the juxtamembrane exon 14 splice sites in NSCLC lead to increased MET stability and oncogenesis. We present the largest cohort study… […]

  • Comprehensive analysis of cancers of unknown primary for the biomarkers of response to immune checkpoint blockade therapy

    – Caris Life Sciences

    Poster

    Background: Carcinoma of unknown primary (CUP) accounts for approximately 3% of all malignancies. Identification of common cancer pathway alterations (hallmarks of cancer) in diverse cancer… […]
Learn More

Ready to Get Started on the Journey?

Name(Required)